GNCA - Earnings call transcript Q1 2021 | Genocea Biosciences, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day and thank you for standing by. Welcome to the First Quarter 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation there will be a question-and-answer session. [Operator Instructions] I would now like to hand the conference over to your speaker today, Dan Ferry. ahead. go Please

Dan Ferry

under and a Operator, plan everyone. today, at Earlier discuss Thank release good that issued genocea.com, available is press This we Investors outlines we tab. today. you, release morning, the the to topics

Officer; Clark, call Chief will Company’s provide and the After Diantha Officer, Duvall corporate During the President and the financial remarks, brief results. update CEO, up Chip the today, the available Financial a Davis, call for will Jessica Chip, review prepared Scientific and Chief Tom Medical questions. to be open Q&A Genocea’s Diantha, Officer, Chief will and your then Genocea’s Flechtner, we will answer

provide to whether Before Reform we are my events to statements It otherwise. now other from may XX-K the filed the Risk is many include to Harbor Act. to Litigation relating differ Factors results statements such the call to to with Exchange set beyond Securities to of that the its begin, Genocea’s intended Genocea Chip. XXXX directed call annual provided defined periodic could over reports future and to are Forward-Looking Commission. impact Securities forth Act on expected Actual Statements Participants expressly of by duty Form or any pass Genocea’s report of forward-looking factors All everyone plans Safe in the the and pleasure subject Genocea. as the future statements, new result as disclaims forecasted Reform due or I a to control and protection information, of updates events XXXX. under future like forward-looking remind future Private the during prospects, conference outcomes those to be made materially this performance, would business

Chip Clark

Dan. And today. for thank us Thanks, joining all you

several GEN-XXX. I GEN-XXX on efforts. We start two our programs updates important will and clinical with to provide are pleased

prioritized discovery peripheral refractory checkpoints T-Cells testing proprietary other GEN-XXX Targeted hold therapy, and antigen reminder, people As Peripheral is T-Cells on are in better or In ATLAS T-Cells, we therapy, to using better taken We and tumors. a initially the words, believe with easily targets cost neoantigens expanding which inhibitor patient’s give NPT tumor blood accessible Neoantigen solid the Genocea’s key T-Cell efficacy, only may may by accessibility other advantages and over T-Cell GEN-XXX, our therapies. platform success. from

single study, the We with a cohorts, patients of types dosing multiple designed TITAN other Phase and evaluate study tumor a two of are a GEN-XXX to conducting currently dose, safety, and doses. administered with X/Xa the across antitumor GEN-XXX efficacy range activity as biomarkers with one in low

accrue continue trial. add We the and to clinical into sites patients

will and the provide in to XXXX. throughout from the fourth a report first subset or quarter updates expect year of patient quarter the late XXXX efficacy of initial We

sensitive our our GEN-XXX, update, top checkpoint resist including and initial to turn a nine we neoantigen patients GEN-XXX, vaccine. me CR. experienced Five inhibitors. with had in let In novel volume dosing activity on responses of independent patients CPI reported GEN-XXX disease evidence post and PRs Now last vaccination. CPI of achieved three additional two tumor post peptide one patients adjuvanted dosed sensitive GEN-XXX control Of shown to reduction clinical

vaccine broad five GEN-XXX resistance anti-tumor have neoantigens. disease. of to T-Cell patients and appeared CDX stabilized seven responses population, and CPI the to elicited CDX Within strong

from to We to long-term June at provide June immunogenicity these clinical study Meeting from are the ASCO monitor continuing expect Xth. this XXXX data follow-up to and Xth Annual patients and

our from explore ATLAS We also insights and continue platform. develop to

can be a and that presented reverse can and presence intended therapies completely effect four new what responses, days data the first inhibiting, as the post immunotherapy been conference, of have single tumor pro of to we seen the antigens early recent AACR anti-tumor We call T-Cell otherwise At the highlighting inhibited identify responses. protective as the inhibiting dosing. we

enable look X and all generation strains. our our additional T-Cell also efforts research to antigens identify to wide updates may activities responses clinical range the that forward of protective of We of research providing year. vaccine SARS We protecting on next a continue COVID against a throughout

from to recently will at our opening Diantha. financials oncology role experience that Jacquelyn to and Chief a therapy now this Diantha doubt XX-years our I’m up biopharmaceutical contributor addition expertise significant focus development on quarter appointing with Jackie several and summarize Sumer, leadership commercialization. executive our In to over team her operational leadership as of and we legal call progress, Legal going pass before I the progress. over to Officer. to be Compliance a no companies questions. including this strengthened call cell have brings held and the to

Diantha Duvall

and you, XX morning, December the with XX ended Thank Jess, XXXX. equivalents of We and good quarter everyone. cash with XX.X million compared at million cash

existing period million, Other of same In Our million our the the results loan. period XXXX. XXXX, XX million were portion the are expenses for compared period X.X net with is remainder end was million to ended XX a call was period With and X.X compared operating income to expenses with for the up XX Operator. questions. for for of XX the operating R&D for term runway extend let’s compared same our X.X million quarter the same million the the XXXX. XXXX. loss XXXX. along that, now X.X we compared million refinancing And million in debt X.X our to were same cash cash March refinance million $XX plan our as February Debt XXXX. open G&A a in in paid to for follows. XXXX to

Operator

the Stifel. with a have question of from You Ben Instructions] Burnet line [Operator

Benjamin Burnett

I morning. - wanted and otherwise to showing work, binary of AACR do a see you your ask vaccine expounding is of range on on the inhibition a that data model. I our depending data is like the good it if if Inhibigen sort ask is around for questions. kind effect of animal inclusion taking based inhibiting Thank provided inhibitory known and interesting or rather some an on you specific some you inhabitant of Hey that the included? of recently effective inhibiting diminished to it wanted

Chip Clark

Yes, will the Ben, for question. handle I to that. ask thanks Jess

Jessica Flechtner

It question. it with one, we studying. to spectrum are repeatedly year shown antigen the a have We sub I completely disease an have data but dominant the it impacts that at itself one Ben. the think before Inhibigens of most but and both a also have a is great as morning, not there on reversing that it Good indeed AACR, recent dominant, is ago, but the reported, can I completely impact, the be last believe, that we the phenotype. from being depends on And and isn’t the is

Benjamin Burnett

a checkpoint defect there I didn’t guess, interesting. accessing tumor is have [indiscernible], of Okay, guess, a by with guess the that surprising this is I just much notion seem consistent inhibitor that adding impact, an and that to it is microenvironment? I in

Jess Flechtner

We deleterious that thought of too Inhibigen and inhibitor of effects the the help recover addition the of checkpoint a the could on presence maybe some response. of the

were So we surprised.

different that still or in helps on these I mechanism avoid maybe think it us know I particular we us we because it the But these helps the overcome really for also it them. directions case points our therapies, us solidify need think don’t responses. currently how understand to to to

Benjamin Burnett

the nuance questions. I and agree to totally these answer appreciate Okay,

thank So, you.

Chip Clark

Ben. you, Thank

Operator

line the Needham. from question a of Chad have Messer with You

Chad Messer

to Jess, I’m set. and thanks for Great. Chip, Good obviously morning one/one, the up. good a excited catch very data

peripheral there of any different, Just issues know your wondering know release are issues? and some recently have similar paying whether yours is kind any of I are you to bands unison you IO would into that sort FDA on learned ran attention there anything wondering blood, and reason be criteria. or the to with stuff to would believe not CMC just

Chip Clark

way. is of - issue not one that the that is have important specific we same on ask release question. our IND Jess at I this have be have in was but will should fact it why Chad least we based today think reasonably package, some And we to about part face the we confidence more the that reasons we addressed it

Jessica Flechtner

Chad. Yes, morning good

have with it bystander what some We of indeterminant we because are the agency the order and from can this is very tumors of poised is I cells. assure potency where characterized. appropriately. than in are standard the product and little little non-specific is the presence in thing. of the understand to good specificity plans and Chip the expansion are understand non-tumor doing we As product a release T-Cells the of about cells the therapies sure job the that make our specificity we bit the to our into is test for different specific and is bit a their that And the do that you said, we right or in written well conversations had itself, our IND our test have GEN-XXX

So, of the well by we potency. perhaps are terms some and product of our characterized tests I the we to virtue no and issues. release don’t in that have I want poised have place think of less say to issues put in being beginning, from

Chad Messer

Alright, Maybe probing the great. Yes thank one work doing. you a that on you that. for just COVID are

a question for with You are attention looking big, to antigens Covid lot big obviously; or are of all the we now, common variants paying for right conserved a future.

sort guys able going information you now? is you will there what many of at you a bearings to the keep able out And think there? up access do Just current overtime? based access you wondering - that What of job you the are how do w able be to? to do are good sort How it look are to with you of much how get your this availability? can on feel be to is How to

Chip Clark

available access to Jess that is will of a important think response issue. give focusing be on antigens case it on here. Yes, you why about to partly more I lot a is the an have color it variants, sort information should But also of is we certainly T-Cell but

Jessica Flechtner

and that same targeting region are - and variants same of you know mutations, fast Right, essentially true antibodies all are protein. furiously, is they and as drive the can same types the because the the protein these and it emerging

that We have published T-Cells of same to people T-Cell of different targets responses the to the tend same or diversity, of because antigen, have protein. in the mutate the in way, different don’t past pieces different

that immunity. We protective equal not antigenicity does also know

response So just measure response you productive. that is T-Cell T-Cell can because that doesn’t a mean

is responses, what to exposed who to are those way and as that virus it from understand And perhaps with looking their people opposed the disease. themselves doing this correctly are who and are are severe exposed, we protect to have so T-Cell

have We libraries. screen the ATLAS large opportunity large proteomes to or with

changes, have in that screening we the immunity parental to as existing subjects stream are doing against benefit identified in our the immunity. to are originally we there addition that on we if changing and you regions can we mountains, them so of And as And understand how of are library. And is, adding done emerge, the what aren’t protective is are are because as mutations, China. with this both the was that associated well

it I in an So an is exciting that And will World update at Vaccine it. giving the my Congress talk. next is week project. be

Chad Messer

that and Thank you. All done guys very based science impressive. taking adding to antigen see edge nice, to on great, the cutting Alright, you glad work is your that. COVID being and all

Chip Clark

Chad. you Thank

Operator

Instructions] [Operator from with line a Kusy the Baird. have You of question Colleen

Colleen Kusy

one do good so of terms the throughout progress? of our questions. guess of XQ updates clinical for sort provide the morning. XXXX, of in or what to efficacy Hi XQ taking GEN-XXX Thanks year ahead much expect I

Chip Clark

Colleen. Thanks

One updates enrollment that providing. I progress think there of will we couple are types dosing. is on be a different and certainly of just

be manufacturing successes. could progress Another on

think the think I important. here, clinical people we data, confidence very process proceeding successfully to are the toward much And that giving be is is so, going product I since

Colleen Kusy

can you. I helpful, if really Inhibigens. on thank is couple that ask Great, And of a

have inhibitory? any less curious more Just targets evolved on become you over is would if guess, any time Inhibigens suggest I data that data to longitudinal that there or

Chip Clark

is and definitely for interesting Jess. That

Jessica Flechtner

I have so have those we And In our human that what in follow the to if we that patients? to clinically. way happens to models, profile? ask. think, treating same something our tracking Inhibigens we we So treat Inhibigenic continue What them we prior are studies, happens will in not that continue work animal the yet we develop done that to is as you after programs

question. well antigens or And to to both antigens. good those it tumor the think as response antigen The a is expression of particular pertains to itself. really as the those that it immune I

so I can will at And you, future. in we assure that is something the it look

Colleen Kusy

on in Inhibigens you seen one look versus any another have guess specifically? I in And you. Thank Great. peripheral amount Is difference there Inhibigen. tumor the the that find Inhibigens of when in or you you the that blood percentage

Jessica Flechtner

question. good also is That a

to able been do haven’t that kind We of yet. work

are in don’t have information. be I to but looking the answer model We the question, to mouse able that

Colleen Kusy

question. my taking for Thanks Okay.

Chip Clark

Colleen. Thanks

Operator

There this are time. in questions no queue at additional

Chip Clark

for throughout then Thank this to will thank look I much. everybody to that, call With forward the updates you attention year. very their with providing and you

Operator

Ladies and conference. conclude this does gentlemen, today’s

disconnect. You now may

Genocea Biosciences (GNCAQ) 29 Apr 212021 Q1 Earnings call transcript